edoxaban

Known as: Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1964-2017
010020019642017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
To review the use of the novel oral anticoagulant (NOAC) agents for the treatment of heparin-induced thrombocytopenia (HIT) from… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
 
  • figure 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) study of a single ascending dose (SAD… (More)
  • table I
  • figure 1
  • table II
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The primary objective of this study was to compare the safety of four fixed-dose regimens of edoxaban with warfarin in patients… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and… (More)
  • figure 1
  • table II
  • table III
Is this relevant?